Novartis Pharmaceuticals

NYSE NVS · Basel, Switzerland

Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health

Novartis Pharmaceuticals is a clinical trial sponsor based in Basel, Switzerland, listed as NYSE NVS. It has 365 active clinical trials with 215,946 planned participants, across 17 therapeutic areas. Since 2021 it has completed 718 trials and stopped 209 early. Its FDA record on file shows 1 inspection.

Trial track record · since 2021

365Active trials215,946 planned participants
718Completed525 with results posted
209Stopped early23% of finished trials

FDA record

1InspectionLatest 2026-06-24: No action indicated
0Warning lettersNone on file
0RecallsNone on file

Recent FDA actions

Financials · NYSE NVS

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Fundraising

Pipeline · 365 active trials

StageTrialStatus

On the market

73 approved drug applications with a product on the market.

Questions about Novartis Pharmaceuticals

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-11-06.

The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.

Approve Suite is not affiliated with Novartis Pharmaceuticals.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.